Gencurix Inc. (KOSDAQ:229000)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,615.00
+70.00 (2.75%)
Apr 1, 2026, 3:30 PM KST
Market Cap61.26B +115.2%
Revenue (ttm)3.39B +25.7%
Net Income-12.55B
EPS-877.76
Shares Out23.43M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume594,069
Average Volume3,130,134
Open2,650.00
Previous Close2,545.00
Day's Range2,545.00 - 2,655.00
52-Week Range1,385.00 - 7,320.00
Beta1.69
RSI42.79
Earnings DateMar 20, 2026

About Gencurix

Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detection. The company has a strategic alliance with Qiagen N.V. for the development of oncology assays for use on the QIAcuityDx platform. The company was fo... [Read more]

Industry Medical - Specialties
Sector Healthcare
Founded 2011
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 229000
Full Company Profile

Financial Performance

In 2023, Gencurix's revenue was 2.60 billion, an increase of 1.60% compared to the previous year's 2.56 billion. Losses were -19.26 billion, -21.70% less than in 2022.

Financial Statements